Revenue
2014
2015
2016
2017
2018
2019
2023
2024
2025
Synergy CHC Corp. (SNYRQ)
Price—Loading quote
Net income
2011
2012
2014
2015
2016
2017
2018
2019
2023
2024
2025
Free cash flow
2015
2016
2017
2018
Total cash / debt
CashTotal debt
2011
2012
2014
2015
2016
2017
2018
2019
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4M | $34.8M | $42.8M | $29.4M | $33.8M | $35.6M | $34.8M | $13.5M | $9,158 | N/A | N/A |
| Gross profit | $20.3M | $23.6M | $32.1M | $20.2M | $22.8M | $25.8M | $24.6M | $8.1M | $3,542 | N/A | N/A |
| Gross margin | 66.83% | 67.87% | 74.99% | 68.87% | 67.37% | 72.42% | 70.71% | 60.55% | 38.68% | N/A | N/A |
| Operating expenses | $28.8M | $17.8M | $21.3M | $28.2M | $27.7M | $24.0M | $21.7M | $7.7M | $961,636 | $21,783 | $15,000 |
| Operating income | −$8.5M | $5.8M | $10.8M | −$8.0M | −$4.9M | $1.8M | $2.9M | $486,023 | −$958,094 | N/A | N/A |
| Operating margin | −27.84% | 16.65% | 25.26% | −27.10% | −14.54% | 5.12% | 8.42% | 3.61% | −10,461.83% | N/A | N/A |
| EBITDA | −$8.3M | $5.9M | $10.8M | −$6.7M | −$3.1M | $3.3M | $4.1M | $1.1M | −$958,094 | N/A | N/A |
| EBITDA margin | −27.40% | 17.04% | 25.34% | −22.97% | −9.15% | 9.31% | 11.78% | 8.13% | −10,461.83% | N/A | N/A |
| Net income | −$12.3M | $2.1M | $6.3M | −$9.2M | −$6.2M | $499,568 | −$796,161 | −$7.5M | −$960,092 | −$23,201 | −$16,200 |
| Net profit margin | −40.62% | 6.10% | 14.82% | −31.36% | −18.21% | 1.40% | −2.29% | −56.01% | −10,483.64% | N/A | N/A |
| Basic EPSper basic share | -$1.27 | $0.28 | $0.86 | -$0.10 | -$0.07 | $0.01 | -$0.01 | -$0.11 | -$0.01 | $0.00 | $0.00 |
| Diluted EPSper diluted share | -$1.27 | $0.28 | $0.86 | -$0.10 | -$0.07 | $0.01 | -$0.01 | -$0.11 | -$0.01 | $0.00 | $0.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Ross Jack | 4.8M |
Knight Therapeutics Inc / KNIGHT THERAPEUTICS INTERNATIONAL SA | 1.48M |
Kaushal Nitin | 306.43K |
SoRelle James Paul | 108.96K |
Thompson Teresa Brigid | 25.82K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Oct 21, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 30, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 100 | $3.69 | $369.00 | 410.5K |
| Jul 29, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 250 | $3.66 | $915.00 | 410.4K |
| Jul 25, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 350 | $3.90 | $1.4K | 410.2K |
| Jul 24, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 300 | $3.83 | $1.1K | 409.8K |
| Jul 22, 2025Form 4 | Ross JackCEO and Chairman | BuyCommon Stock, par value $0.00001 per share | 300 | $3.54 | $1.1K | 409.5K |